Patient Derived Xenograft (PDX)

*** Use of patient-derived xenograft models requires signed agreement ***

Patient-Derived Xenograft (PDX) models represent the cutting edge of cancer drug development, increasing our ability to advance novel, active agents into patients. A joint effort between the Pathology Core Facility and the Center for Developmental Therapeutics, the project uses a systematic approach to develop models across multiple tumor histologies in a way that benefits the entire institution. This repository allows many basic oncology research questions to be addressed using annotated tissue and models that closely resemble human cancer rather than cell lines.

Xenograft model or heterotransplantation of human cancer cell lines into immunodeficient mice has served for decades as the major preclinical screen for the development of novel cancer therapeutics. However, current cell line-xenograft tumor preclinical models could not predict success of oncology drug development. When the model of the xenograft tumor established from cancer cell line is used, novel therapeutics that were 97% successful in in vivo studies fail in clinic.

We have developed PDX tumor models of 12 different types of human cancer including:

  • Acute Myeloid Leukemia (AML)
  • Bladder
  • Breast
  • Colon
  • Endometrial
  • Glioblastoma (GBM)
  • Liver
  • Lung
  • Mesothelioma
  • Multiple Myeloma
  • Ovarian
  • Pancreatic
  • AML

    Type ID# Initial Trans. Date Age and Sex
    AML, Blood   8/26/13  37, F

    Bladder

    Type ID# Initial Trans. Date Age and Sex
    Urothelial    5/1/14  
    Bladder  NUBCA01  1/11/16   76, M
    Bladder  NUBCA02  3/2/16   71, M
    Bladder  NUBCA03 3/9/16   85, M
    Bladder  NUBCA04  4/6/16   71, F

    Breast

    Type ID# Age and Sex Status
     Breast, pleural effusion  NUBC01    ER+/PR+/HER2-(early passages) and ER+/PR+/HER2+ (late passages)
     Breast, pleural effusion  NUBC02  39, F  ER+/PR+/HER2-(early passages) and ER+/PR+/HER2+ (late passages)
     Breast, pleural effusion  NUBC03    
     Breast, primary   NUBC04  67, F  
     Breast, pleural effusion  NUBC05  47, F  
     Breast, primary   NUBC06  38, F  
     Breast, primary   NUBC07  46, F  
     Breast, pleural effusion  NUBC08  48, F  HER2+

    Colon

    Type ID# Initial Trans. Date Age and Sex
     Colon  NUCRC01  4/2/13  86, F
     Colon  NUCRC0  4/4/13  61, F
     Colon  373893  6/18/13  

    Endometrial

    Type ID# Initial Trans. Date Age and Sex
    Endometrial NUEC178    

    GBM

    Type ID# Initial Trans. Date Age and Sex
     GBM NUGBM01  2/27/13  49, M
     GBM NUGBM02  4/10/13  65, F

    Liver

    Type ID# Initial Trans. Date Age and Sex
     HCC  NUHCC01 10/28/15  71, F

    Lung*

    Type ID# Initial Trans. Date Age and Sex
    Lung, Pleural Effusion* NUPELC01 1/15/14  79, M

    Mesothelioma

    Type ID# Initial Trans. Date Age and Sex
     Mesothelioma    12/30/13  63, M
     Mesothelioma  NUPEMC01  3/14/14  

    Multiple Myeloma

    Type ID# Initial Trans. Date Age and Sex
    Multiple Myeloma    9/18/14  NA

    Ovarian

    Type ID# Initial Trans. Date Age and Sex
    HGSC NUOVCA4    
    HGSC NUOVCA5    
    HGSC NUOVCA6    
    HGSC NUOVCA7    
    HGSC NUOVCA8    
    HGSC NUOVCA9    
    HGSC NUOVCA10    
     HGSC  NUOVCA12    
     HGSC  NUOVCA13    

    Pancreatic

    Type ID# Initial Trans. Date Age and Sex
     PDAC  NUPDAC01 5/6/13  62, M
     PDAC  NUPDAC02  5/28/13  68, F
     PDAC  NUPDAC03  6/28/13  60, M
     PDAC  NUPDAC04  10/13/14  
     PDAC  NUPDAC05  4/27/15  
     PDAC  NUPDAC06  7/20/15  
     PDAC  NUPDAC07  7/21/15  
     PDAC  NUPDAC09  1/27/16  

 

Patient derived xenograft (PDX) tumor models emerged as a new approach for preclinical testing of novel anticancer compounds in vivo due to its preservation of key features, which includes invasiveness, stromal reaction, tumor vasculature and cellular diversity of human carcinomas. In contrast to a cell line-xenograft tumor model, PDX tumors are established from the transplantation of fresh tumor tissue from a cancer patient into a immunodeficient mouse.

Fresh tumor samples were obtained from cancer patients immediately after surgical resection. Initially, we transplanted a small piece of fresh human tumor tissue either subQ or intraperitoneally and then passaged the xenograft tumors in mice to expand the amount of tumor tissue frozen. We reproducibly use our frozen stock to establish PDX tumors for future in vivo studies. All PDX tumor models are available to NU research community. Please contact i-kandela [at] northwestern [dot] edu (subject: PDX%20Model) (Irawati (Angki) Kandela), Assistant Director of the Developmental Therapeutics Core, for more information about program development and PDX tumor availability.

The project is supported by the Baskes Foundation and Robert H. Lurie Comprehensive Cancer Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Baskes Foundation and Robert H. Lurie Comprehensive Cancer Center.